trial

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

NCTId NCT06504290
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 40 (estimated)
Sponsored by Vigonvita Life Sciences
Primary completion 2026-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2024-07-16
Primary completion
2026-07-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
VV119 （in healthy adult subjects）VV119(in adult patients with schizophrenia)

Sponsors

Vigonvita Life SciencesLead Sponsor

Investigators

1
Gang Wang, MDPrincipal Investigator

Sites

4 total
Beijing, ChinaBeijing, ChinaBeijing, ChinaXi’an, China

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2026-07-01
Status
RECRUITING
relationships
The graph out of here
drug
VV119 （in healthy adult subjects）
drug
VV119(in adult patients with schizophrenia)
drug
lead_sponsor
Vigonvita Life Sciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gang Wang, MD
person